CergenX
Irish neonatal neurotechnology startup building an AI-guided EEG screening device for early detection of brain injury in newborns.
What They Do
CergenX is developing CergenX Wave, an AI-powered neonatal brain-monitoring system designed to screen newborns for signs of brain injury in minutes rather than requiring specialist neurophysiology interpretation. The company frames the product as decision support for frontline clinicians, not just tertiary-neurology experts, which matters in NICUs and delivery settings where early neurological assessment can be delayed. Its commercialization model appears provider-facing and device-led, with Enterprise Ireland backing and UCC spinout roots rather than a consumer or reimbursement-led go-to-market strategy. I did not find public evidence of a disclosed payer mix or broad commercial deployment yet.
Competitive Position
CergenX overlaps most directly with neurobell and the neonatal expansion efforts of ceribell, while also trying to displace incumbent aEEG interpretation workflows from Natus and similar vendors. Its differentiation is the emphasis on short-form AI-assisted screening for newborn brain injury risk, which is a slightly broader framing than seizure-only detection. The open question is whether that screening-first positioning will translate into a clear purchasing wedge versus better-funded seizure-monitoring incumbents and startups.
Funding Rounds
No funding rounds on record for this company.